Tag

Amyloid Beta

All articles tagged with #amyloid beta

science8 days ago•5 min saved

Nanoparticles Restore Brain Cleanup, Reversing Alzheimer’s Signs in Mice

Researchers used supramolecular nanoparticles that act as drugs to repair the brain's blood-brain barrier and restart its waste-clearance system. In mice with high amyloid-β, three injections reduced brain Aβ by 50–60% within an hour, with months-long vascular and cognitive improvements; the approach leverages the LRP1 transport system to reset clearance. While promising, the work is in animal studies and human trials remain years away.

via ScienceDaily|

#alzheimers-disease #amyloid-beta #blood-brain-barrier

science12 days ago•10 min saved

Common amino acid arginine slows Alzheimer’s pathology in animals

Japanese researchers found that arginine, a safe and inexpensive amino acid, reduced amyloid-β aggregation, decreased brain inflammation, and improved behavior in fruit flies and mice models of Alzheimer’s disease. The effects appear to come from interfering with protein misfolding rather than lowering production. While promising and eligible for repurposing, the work is preclinical and dosing differs from dietary supplements, so larger preclinical and human studies are needed before clinical use.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #arginine

health-and-medicine22 days ago•6 min saved

Affordable Arg: Arginine Slows Alzheimer’s Damage in Animal Models

A Kindai University study shows that the inexpensive amino acid arginine can reduce amyloid-β buildup and brain inflammation in Alzheimer’s models (flies and mice), improving behavior; given its safety and low cost, arginine could be a rapid candidate for repurposing, but human trials and optimal dosing are still needed.

via ScienceDaily|

#alzheimers-disease #amyloid-beta #arginine

science23 days ago•35 min saved

Midlife clues reveal Alzheimer’s may start decades before memory loss

A Mayo Clinic study finds Alzheimer’s-related changes can begin in people’s late 50s, decades before memory problems, outlining a two-phase timeline where amyloid buildup appears first, followed by other biomarkers and cognitive changes as people age, with blood and imaging signals peaking later. The research warns that averages don’t predict an individual's onset and suggests earlier, smarter screening and planning, while noting limitations in population diversity and the need for clearer clinical guidelines.

via Earth.com|

#aging #alzheimers #amyloid-beta

health27 days ago•5 min saved

GLP-1 diabetes medicines show potential to curb Alzheimer's protein buildup in preclinical studies

A new review of mostly preclinical studies links GLP-1 diabetes/weight-loss medications (e.g., semaglutide, liraglutide) to reduced amyloid-beta plaques and tau tangles in cells and animals, with only two small human trials reporting mixed results; still early evidence and larger clinical trials are needed to confirm cognitive benefits.

via ScienceAlert|

#alzheimers-disease #amyloid-beta #clinical-trials

science1 month ago•6 min saved

GLP-1 Diabetes Drugs Target Alzheimer’s Pathology in Animal Studies

A systematic review of 30 preclinical studies finds GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide) consistently reduce Alzheimer's hallmarks amyloid-beta plaques and tau tangles in animal and cell models, with liraglutide showing the strongest and most consistent effects; human data are limited and mixed so far, though some trials show preserved brain glucose metabolism and inflammatory marker changes, suggesting these drugs may help prevent dementia if used earlier rather than cure established disease.

via Neuroscience News|

#alzheimers-disease #amyloid-beta #glp-1-receptor-agonists

health1 month ago•2 min saved

Amyloid-Targeting Alzheimer’s Drugs Show No Meaningful Benefit and Increase Brain Risks

A Cochrane review of 17 trials (20,342 participants) finds anti-amyloid drugs for Alzheimer’s disease do not provide clinically meaningful cognitive or daily-function benefits in mild cognitive impairment or mild dementia and may raise risks of brain swelling and bleeding, despite removing amyloid-beta from the brain. The evidence suggests these drugs do not translate into patient benefit, prompting a shift toward exploring other treatment pathways.

via Cochrane Collaboration|

#alzheimers-disease #amyloid-beta #anti-amyloid-drugs

science1 month ago•7 min saved

Intracellular Tug-of-War Between Amyloid Beta and Tau Redefines Alzheimer's Cause

UC Riverside researchers propose that Alzheimer’s disease may arise from a competition inside neurons where amyloid beta and tau vie for the same microtubule binding sites, disrupting intracellular transport; this could mean plaques are a downstream effect rather than the root cause and shift therapy toward preventing this intracellular interference or boosting protein clearance.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #microtubules

science2 months ago•6 min saved

Microtubule Nexus Reframes Alzheimer's: Amyloid Beta Displaces Tau

A new study suggests Alzheimer's may start when amyloid beta competes with tau for binding to microtubules in neurons, displacing tau and destabilizing the cell’s transport system. This microtubule nexus could unify amyloid- and tau-centered theories and open pathways for therapies that target tau displacement from microtubules.

via SciTechDaily|

#alzheimers #amyloid-beta #microtubules

science2 months ago•8 min saved

Hidden P3 Peptide Emerges as a Potential Alzheimer’s Driver

UC Santa Cruz researchers show the overlooked P3 peptide (also called Amyloid α), produced from the same amyloid precursor protein as amyloid beta, can form amyloid deposits and may contribute to neuron damage, challenging the Aβ-centric view of Alzheimer’s and suggesting new therapeutic avenues.

via SciTechDaily|

#alzheimers-disease #amyloid-alpha #amyloid-beta

health2 months ago•4 min saved

Engineered T cells reduce Alzheimer's plaques in mice, a first for neurodegenerative disease

Washington University researchers used CAR-T cell therapy to reprogram brain immune cells to recognize and clear amyloid beta plaques in mice, reducing plaques and dampening neuroinflammation. This is the first application of CAR-T to a neurodegenerative disease, but it is early-stage and not yet ready for humans; scientists plan safety and dosing studies and will explore translation to other disorders, with potential relevance for veterans at risk of dementia.

via Military.com|

#alzheimers-disease #amyloid-beta #car-t-therapy

science2 months ago•7 min saved

Real-Time Metal Signals Reveal How Alzheimer’s Proteins Clump—and How to Undo It

OSU researchers captured real-time, second-by-second interactions that drive copper-associated amyloid-beta protein clumping in Alzheimer’s, showing that carefully targeted chelators can interrupt or reverse aggregation and providing a roadmap for more precise therapies, with future tests in cellular and preclinical models.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #chelators

science2 months ago•6 min saved

CAR-astrocytes: engineered brain cells purge Alzheimer's plaques in mice with one injection

Researchers engineered astrocytes to express a CAR targeting amyloid beta, turning them into brain “super cleaners.” In mice, a single gene-therapy injection either prevented plaque formation when given early or reduced existing amyloid plaques by ~50%, signaling a potential new immunotherapy approach for Alzheimer's—though safety and human trials remain to be established.

via ScienceAlert|

#alzheimers-disease #amyloid-beta #astrocytes

science-and-tech2 months ago•263 min saved

Old seizure medicine shows potential to prevent Alzheimer's decades before symptoms

Northwestern University researchers report that levetiracetam, a long-used anti-seizure drug, may prevent Alzheimer’s by blocking the production of amyloid-beta 42, the protein linked to plaques, with results seen in animal models and cultured human neurons (and post-mortem Down syndrome brain tissue). If taken decades before symptoms, it could theoretically slow or prevent disease, though there are no human trials yet and the evidence is observational; researchers caution that the drug would need to start very early and are pursuing longer-lasting formulations and trials, including in genetic forms of Alzheimer’s.

via AOL.com|

#alzheimers-disease #alzheimers-prevention #amyloid-beta

health2 months ago•9 min saved

Repurposed Seizure Drug Could Prevent Alzheimer’s Plaque Formation

Northwestern researchers identify that the Alzheimer’s-related amyloid-beta 42 peptide accumulates inside presynaptic vesicles, and that the FDA-approved anti-seizure drug levetiracetam blocks its production by binding SV2A and slowing vesicle recycling, shifting APP away from the Aβ42-producing pathway. The findings in animal models, cultured human neurons, and Down syndrome brain tissue suggest a very early preventive approach—levetiracetam would need to be taken long before symptoms for a potential reduction in risk. A review of clinical records hints a modest delay in cognitive decline-to-death for patients on levetiracetam, supporting a possible benefit, while researchers urge developing longer-acting versions and testing in inherited Alzheimer’s forms. Importantly, this would not treat established dementia.

via SciTechDaily|

#alzheimers-disease #amyloid-beta #app-processing